BamSEC and AlphaSense Join Forces
Learn More

Vor Biopharma Inc.

NASDAQ: VOR    
Share price (1/9/26): $13.52    
Market cap (1/9/26): $296 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 10 pages As We Have Agreed, You Will Separate From Employment With Vor Biopharma Inc. (“VOR” or “Company”) Effective December 31, 2025 (Your "Separation Date"). This Separation Agreement Contains Our Agreement Regarding the Finalization of Your Work, Your Separation and Your Agreement to Certain Matters Important to Company, Including a General Release of Claims (The “Separation Agreement” or “Agreement”). 1. Final Wages: On or Before Your Separation Date, Payment of Your Final Wages Will Be Made and Is Not Contingent Upon Your Signing This Separation Agreement. Because the Company Has an Unlimited Pto Policy, You Have No Accrued and Unused Pto. 2
12/34/56
EX-10.2
from 8-K 17 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 37 pages Securities Purchase Agreement
12/34/56
EX-10.6
from 10-Q 3 pages Amendment to Employment Agreement
12/34/56
EX-10.1
from 8-K 35 pages Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan Adopted by the Board of Directors: July 28, 2025 Approved by the Stockholders: August 25, 2025
12/34/56
EX-10.10
from 10-Q 51 pages 500 Boylston Street Boston, Ma Office Lease Agreement Between 500 Boylston & 222 Berkeley Owner (De) LLC, a Delaware Limited Liability Company, as Landlord and Vor Biopharma, Inc., a Delaware Corporation, as Tenant Office Lease Agreement
12/34/56
EX-10.9
from 10-Q 68 pages Portions of This Agreement (Indicated by “[***]”) Have Been Omitted as the Registrant Has Determined That: (I) the Omitted Information Is Not Material; and (II) the Omitted Information Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.1
from 8-K 15 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 15 pages Employment Agreement
12/34/56
EX-10.7
from 8-K 16 pages Employment Agreement
12/34/56
EX-10.6
from 8-K 11 pages June 25, 2025 Robert Ang via Email Re: Transition Agreement Dear Robert: This Letter Sets Forth the Substance of the Separation Agreement (Hereinafter, “Agreement”) Which Vor Biopharma Inc. (Hereinafter, “The Company”) Is Offering to You to Aid in Your Employment Transition
12/34/56
EX-10.5
from 8-K 9 pages Voting and Support Agreement
12/34/56
EX-10.4
from 8-K 16 pages Registration Rights Agreement
12/34/56
EX-10.3
from 8-K 37 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 35 pages Portions of This Agreement (Indicated by “[***]”) Have Been Omitted as the Registrant Has Determined That: (I) the Omitted Information Is Not Material; and (II) the Omitted Information Is the Type That the Registrant Treats as Private or Confidential. Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 17 pages Pre-Funded Warrant to Purchase Common Stock
12/34/56
EX-10.17
from 10-K 3 pages Material contract
12/34/56
EX-10.2
from 8-K 15 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 39 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Material contract
12/34/56